Browse Category

Investment News News 13 November 2025 - 14 November 2025

Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb and Johnson & Johnson end a key Phase 3 heart study for milvexian, sending BMY stock lower even as the pharma giant leans on a strong growth portfolio and fresh financing firepower. Bristol-Myers Squibb Company (NYSE: BMY)
MDA Space Stock Plunges Over 50% on SpaceX Shock, But Q3 2025 Earnings and Wireless Power Deal Rekindle Bull Hopes

MDA Space Stock Plunges Over 50% on SpaceX Shock, But Q3 2025 Earnings and Wireless Power Deal Rekindle Bull Hopes

Canadian space-tech champion MDA Space faces a brutal rerating after EchoStar’s $1.3 billion contract cancellation and SpaceX‑linked customer buzz – just as it reports surging Q3 revenue, reaffirms guidance, and announces a futuristic wireless power partnership. MDA Space (TSX:MDA) stock
Sealed Air (SEE) Soars to 52‑Week High as Clayton Dubilier & Rice Weighs Take‑Private Deal

Sealed Air (SEE) Soars to 52‑Week High as Clayton Dubilier & Rice Weighs Take‑Private Deal

Sealed Air Corporation (NYSE: SEE), maker of Bubble Wrap, jumped to a 52‑week high on November 13, 2025, as private‑equity firm Clayton Dubilier & Rice reportedly explores a take‑private deal. Here’s what’s driving SEE stock today, including fresh buyout rumors,
Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Vancouver / Jerusalem – November 13, 2025 – Shares of Clearmind Medicine Inc. (NASDAQ: CMND), a clinical‑stage psychedelic and neuroplastogen biotech company, jumped sharply on Thursday after the firm announced final approval to expand its FDA‑regulated Phase 1/2a clinical trial
Firefly Aerospace (FLY) Stock Jumps on Q3 2025 Earnings Beat, Raised Guidance and Alpha Rocket Comeback Plan

Firefly Aerospace (FLY) Stock Jumps on Q3 2025 Earnings Beat, Raised Guidance and Alpha Rocket Comeback Plan

Firefly Aerospace Inc. (Nasdaq: FLY) sent a fresh jolt through the space-stock universe this week, as investors digested a powerful mix of better‑than‑expected third‑quarter results, a higher full‑year outlook, a clearer path back to flight for its Alpha rocket—and a
1 46 47 48 49 50 63
Go toTop